Metformin use decreases the anticoagulant effect of phenprocoumon

Summary Background Anticoagulant therapy with vitamin K antagonists (VKAs) is affected by interaction of the VKAs with a large number of other drugs. Although metformin is generally not considered to interact with VKAs, we observed a decrease in INR after starting metformin treatment in patients usi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2014-06, Vol.12 (6), p.887-890
Main Authors: Wijnen, J. C. F., Riet, I. R., Lijfering, W. M., Meer, F. J. M.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Anticoagulants - therapeutic use
Blood Coagulation - drug effects
diabetes mellitus, type 2
Drug Interactions
Drug Monitoring - methods
Female
Humans
Hypoglycemic Agents - adverse effects
International Normalized Ratio
Male
metformin
Metformin - adverse effects
Middle Aged
Netherlands
phenprocoumon
Phenprocoumon - therapeutic use
Retrospective Studies
Time Factors
warfarin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Anticoagulant therapy with vitamin K antagonists (VKAs) is affected by interaction of the VKAs with a large number of other drugs. Although metformin is generally not considered to interact with VKAs, we observed a decrease in INR after starting metformin treatment in patients using the VKA phenprocoumon. Objectives To investigate the influence of metformin use on the dosage of phenprocoumon and INR in stably anticoagulated patients. Patients We used the database of the Anticoagulation Clinic Leiden for this study. In a population of 369 patients screened, 27 consecutive patients using phenprocoumon were prescribed metformin during the study period (1 January 2007 to 1 March 2009), without use of other concomitant medications or medical interventions that could influence the INR. Results The mean phenprocoumon dosage increased from 2.13 to 2.37 mg per day within 6 weeks (mean increase, 0.23 mg; 95% CI, 0.12–0.34) and 2.49 mg per day within 3 months (mean increase, 0.36 mg; 95% CI, 0.24–0.48) after starting metformin. The mean INR decreased from 2.88 to 2.26 (mean decrease, 0.63; 95% CI, 0.41–0.85) within 6 weeks and 2.54 (mean decrease, 0.35; 95% CI, 0.24–0.48) within 3 months after starting metformin. Conclusions This study shows that clinicians should be aware that metformin treatment may lead to an increased optimal dosage of phenprocoumon.
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/jth.12578